title: [A case of gastric cancer with recurrent bone metastases successfully treated with induced hypertension chemotherapy using cisplatin].
abstract: A sixty-eight-year-old female with bone metastases from gastric cancer successfully treated with induced hypertension chemotherapy using cisplatin is reported. She had undergone R2 curative subtotal gastrectomy in June 1985, and had orally taken tegafur 600 mg/day and then changed to doxifluridine 800 mg/day as postoperative adjuvant chemotherapy. Five months after the operation she had back pains and both 99mTc-MDP and 67Ga-citrate scintigram showed L1 vertebra and rib bone metastasis. Induced hypertension chemotherapy using cisplatin was then intermittently performed from January 1986 to September 1990, a single course of which was 25 mg/body div x 2/week for serial 4 weeks; a total of seven courses were carried out and consequently the total volume of the administered cisplatin reached 1,100 mg. Neither medullar nor renal toxicities were observed, but mild gastrointestinal symptoms were noted. The patient no longer has back pains, and no signs of bone metastases were seen on both scintigrams for two years and eight months from December 1988 to August 1991. This case is very rare because her bone metastases were successfully treated with induced hypertension chemotherapy using cisplatin. However, metastatic bone tumors from gastric cancer usually resist any treatments. It is expected that the successfully treated patients even with bone metastasis will be increasingly reported from now as various new approaches including induced hypertension chemotherapy are introduced.
authors.affiliation: Department of Surgery, Ehime Prefectural Central Hospital, Matsuyama, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kiyasu
authors.forename: Y
authors.initials: Y
authors.lastname: Kashu
authors.forename: K
authors.initials: K
authors.lastname: Sakai
authors.forename: S
authors.initials: S
authors.lastname: Shigematsu
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Furuya
authors.forename: A
authors.initials: A
authors.lastname: Moriuchi
authors.forename: H
authors.initials: H
authors.lastname: Satoh
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000503:physiopathology / Q000556:secondary*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001794:Blood Pressure / Q000187:drug effects*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D011877:Radionuclide Imaging; D013274:Stomach Neoplasms / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D005467:Floxuridine; D005641:Tegafur; D002945:Cisplatin; C025034:doxifluridine